Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.

Rack B, Jückstock J, Genss EM, Schoberth A, Schindlbeck C, Strobl B, Heinrigs M, Rammel G, Zwingers T, Sommer H, Friese K, Janni W.

Anticancer Res. 2010 May;30(5):1807-13.

PMID:
20592383
2.

[Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study].

Rack B, Schindlbeck C, Strobl B, Sommer H, Friese K, Janni W.

Dtsch Med Wochenschr. 2008 Feb;133(7):285-9. doi: 10.1055/s-2008-1046707. German.

PMID:
18253918
3.

The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.

Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K.

Cancer. 2005 Mar 1;103(5):884-91.

4.

Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.

Wiedswang G, Borgen E, Kåresen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B.

Clin Cancer Res. 2004 Aug 15;10(16):5342-8.

5.
6.

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.

Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA; Z-FAST and ZO-FAST Study Groups.

Oncologist. 2008 May;13(5):503-14. doi: 10.1634/theoncologist.2007-0206.

7.

Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G.

J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8.

PMID:
8931609
8.

Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.

Wiedswang G, Borgen E, Kåresen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B.

J Clin Oncol. 2003 Sep 15;21(18):3469-78.

PMID:
12972522
9.

Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients.

Solomayer EF, Diel IJ, Salanti G, Hahn M, Gollan C, Schütz F, Bastert G.

Clin Cancer Res. 2001 Dec;7(12):4102-8.

10.

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).

von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, Hilfrich J, Costa SD, Dubsky P, Blohmer JU, Denkert C, Hanusch C, Jackisch C, Kümmel S, Fasching PA, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S; German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators.

Eur J Cancer. 2016 Sep;64:12-21. doi: 10.1016/j.ejca.2016.05.015. Epub 2016 Jun 17.

PMID:
27323347
11.

[The influence of the hemoglobin concentration on the hematogenous tumor cell dissemination at the time of the initial diagnosis of breast cancer].

Janni W, Strobl B, Rack B, Rjosk D, Schindlbeck C, Hantschmann P, Kentenich C, Sigg W, Zerzer M, Sommer H.

Dtsch Med Wochenschr. 2002 Jan 18;127(3):71-7. German.

PMID:
11797143
12.

Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.

Hohaus S, Funk L, Martin S, Schlenk RF, Abdallah A, Hahn U, Egerer G, Goldschmidt H, Schneeweiss A, Fersis N, Kaul S, Wallwiener D, Bastert G, Haas R.

Br J Cancer. 1999 Mar;79(9-10):1500-7.

13.

Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.

Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E.

J Clin Oncol. 2008 Oct 10;26(29):4739-45. doi: 10.1200/JCO.2008.16.4707. Epub 2008 Aug 18.

14.

Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.

Schneeweiss A, Goerner R, Hensel MA, Lauschner I, Sinn P, Kaul S, Egerer G, Beldermann F, Geberth M, Solomayer E, Grischke EM, Haas R, Ho AD, Bastert G.

Biol Blood Marrow Transplant. 2001;7(6):332-42.

15.

Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.

Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X, Pierga JY; Institut Curie Breast Cancer Study Group.

Clin Cancer Res. 2008 Jun 1;14(11):3306-11. doi: 10.1158/1078-0432.CCR-07-4749.

17.

Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).

Chapman I, Greville H, Ebeling PR, King SJ, Kotsimbos T, Nugent P, Player R, Topliss DJ, Warner J, Wilson JW.

Clin Endocrinol (Oxf). 2009 Jun;70(6):838-46. doi: 10.1111/j.1365-2265.2008.03434.x. Epub 2008 Sep 24.

PMID:
18823395
18.

Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.

Touboul E, Buffat L, Belkacémi Y, Lefranc JP, Uzan S, Lhuillier P, Faivre C, Huart J, Lotz JP, Antoine M, Pène F, Blondon J, Izrael V, Laugier A, Schlienger M, Housset M.

Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):25-38.

PMID:
9989511
20.

Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.

Kijima T, Fujii Y, Suyama T, Okubo Y, Yamamoto S, Masuda H, Yonese J, Fukui I.

BJU Int. 2009 Mar;103(5):620-4. doi: 10.1111/j.1464-410X.2008.08124.x. Epub 2008 Oct 16.

Supplemental Content

Support Center